#PWID

Hepatitis C commonly spreads through condomless sex and injection drug use among men who have sex with men.

The Centers for Disease Control and Prevention has learned difficult lessons from such outbreaks over the past five years.

A new study’s findings have led researchers to challenge physicians’ biases against certain groups.

As overdose death rates have risen in this population, life expectancy has increasingly narrowed.

The CDC recently expanded its hepatitis A vaccine recommendation and now advises it for all people with HIV older than 12 months.

The nation’s health care system provides unrestricted access to hepatitis C treatment.

Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.

A recent analysis found that health care providers missed opportunities to test 90% of such patients.

A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.

Federal judge rules in favor of nonprofit seeking to open the country’s first overdose prevention facility.

Researchers point to heroin use as a major driver of new hepatitis C and HIV cases among people who inject drugs.

Restricting the testing program to only people who inject drugs did not improve its cost effectiveness.

Opioid use disorder is fueling a rise in youth hepatitis C cases and a stabilization of a long decline in HIV among people who use drugs.

The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.

U.S. health care systems are seeking better solutions to the critical problem of drug diversion.

This includes people who use drugs, those with psychiatric disorders and those with a history of alcohol use.